These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
56 related articles for article (PubMed ID: 2288818)
1. Bone loss in prednisone treated sarcoidosis: a two-year follow-up. Montemurro L; Fraioli P; Riboldi A; Delpiano S; Zanni D; Rizzato G Ann Ital Med Int; 1990; 5(3 Pt 1):164-8. PubMed ID: 2288818 [TBL] [Abstract][Full Text] [Related]
2. Prednisone-induced bone loss in sarcoidosis: a risk especially frequent in postmenopausal women. Rizzato G; Tosi G; Mella C; Montemurro L; Zanni D; Sisti S Sarcoidosis; 1988 Sep; 5(2):93-8. PubMed ID: 3227194 [TBL] [Abstract][Full Text] [Related]
3. Bone loss in untreated longstanding sarcoidosis. Montemurro L; Fraioli P; Rizzato G Sarcoidosis; 1991 Mar; 8(1):29-34. PubMed ID: 1669936 [TBL] [Abstract][Full Text] [Related]
4. Bone mineral density in women with sarcoidosis. Sipahi S; Tuzun S; Ozaras R; Calis HT; Ozaras N; Tuzun F; Karayel T J Bone Miner Metab; 2004; 22(1):48-52. PubMed ID: 14691687 [TBL] [Abstract][Full Text] [Related]
6. Bone protection with salmon calcitonin (sCT) in the long-term steroid therapy of chronic sarcoidosis. Rizzato G; Tosi G; Schiraldi G; Montemurro L; Zanni D; Sisti S Sarcoidosis; 1988 Sep; 5(2):99-103. PubMed ID: 3227195 [TBL] [Abstract][Full Text] [Related]
7. Bone density loss during treatment of chronic GVHD. Stern JM; Chesnut CH; Bruemmer B; Sullivan KM; Lenssen PS; Aker SN; Sanders J Bone Marrow Transplant; 1996 Mar; 17(3):395-400. PubMed ID: 8704693 [TBL] [Abstract][Full Text] [Related]
8. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Montemurro L; Schiraldi G; Fraioli P; Tosi G; Riboldi A; Rizzato G Calcif Tissue Int; 1991 Aug; 49(2):71-6. PubMed ID: 1913297 [TBL] [Abstract][Full Text] [Related]
9. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559 [TBL] [Abstract][Full Text] [Related]
10. Bone mineral density changes in women with systemic lupus erythematosus. Boyanov M; Robeva R; Popivanov P Clin Rheumatol; 2003 Oct; 22(4-5):318-23. PubMed ID: 14579164 [TBL] [Abstract][Full Text] [Related]
11. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Piver MS Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011 [TBL] [Abstract][Full Text] [Related]
12. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Güler-Yüksel M; Allaart CF; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; van Groenendael JH; Mallée C; de Bois MH; Breedveld FC; Dijkmans BA; Lems WF Ann Rheum Dis; 2009 Mar; 68(3):330-6. PubMed ID: 18375540 [TBL] [Abstract][Full Text] [Related]
13. Prednisone-induced osteoporosis: an overlooked and undertreated adverse effect. Shah SK; Gecys GT J Am Osteopath Assoc; 2006 Nov; 106(11):653-7. PubMed ID: 17192452 [TBL] [Abstract][Full Text] [Related]
15. Effect of long-term calcitonin administration on steroid-induced osteoporosis after cardiac transplantation. Kapetanakis EI; Antonopoulos AS; Antoniou TA; Theodoraki KA; Zarkalis DA; Sfirakis PD; Chilidou DA; Alivizatos PA J Heart Lung Transplant; 2005 May; 24(5):526-32. PubMed ID: 15896748 [TBL] [Abstract][Full Text] [Related]
16. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone. Sijanovic S; Karner I Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925 [TBL] [Abstract][Full Text] [Related]
17. Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal women. Delmas PD; Pornel B; Felsenberg D; Stakkestad JA; Radowicki S; Garnero P; Hardy P; Dain MP; Petitier B; Am J Obstet Gynecol; 2001 Jan; 184(2):32-40. PubMed ID: 11174476 [TBL] [Abstract][Full Text] [Related]
18. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Seriolo B; Paolino S; Sulli A; Ferretti V; Cutolo M Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169 [TBL] [Abstract][Full Text] [Related]
19. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Van Staa TP; Laan RF; Barton IP; Cohen S; Reid DM; Cooper C Arthritis Rheum; 2003 Nov; 48(11):3224-9. PubMed ID: 14613287 [TBL] [Abstract][Full Text] [Related]
20. Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. Solomon DH; Katz JN; Jacobs JP; La Tourette AM; Coblyn J Arthritis Rheum; 2002 Dec; 46(12):3136-42. PubMed ID: 12483716 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]